


IQCP?...IDK...

WT  .FTW!

Sheldon Campbell M.D., Ph.D.

VA Connecticut Health Care

Poll Question 1

- You probably know what IQCP stands for. But what *should* it stand for?
 1. Icelanders quietly control Pennsylvania?
 2. Initiate quantum chocolate pie!
 3. I quit completely POC.
 4. Integrated quirky conceptual pizza.
 5. In quarterfinals, crush the Padres!



Learning Objectives

- Participants will be able to:
 - Describe the regulatory and quality of care rationales for Individualized Quality Control Plan (IQCP).
 - Analyze the need for an IQCP, given a particular test system.
 - Describe the elements of an IQCP.
 - Perform and analyze risks related to laboratory testing for IQCP.
 - Find and utilize templates for IQCP from ASM and CAP.
 - Apply their newfound knowledge to IQCP development.

Outline

IQCP

- Historical and regulatory background
- What exactly is an IQCP?

IDK

- What tests are eligible?
- When do you need one?

WT<censored>?

- What are the elements of an IQCP?
- What is a risk assessment and how do I perform them?

FTW!

- Where can you find resources and templates to make IQCP as painless as possible?

IQCP?

What is it? Why do I need it?

Quality Control Under CLIA

- Section §493.1202(c) for **unmodified moderate complexity tests**:
 - assay **at least two levels of control materials each day of testing** (a run cannot exceed 24 hours) and keep records;
 - perform and document any applicable specialty and subspecialty control procedures;
 - perform and document remedial actions as specified in §493.1219;
 - maintain records of all QC activities for 2 years or 5 years for immunohematology and 10 years for pathology as specified in §493.1221.
- For certain tests CLIA requires additional QC:
 - Blood gases, automated hematology and coagulation test systems, manual cell counts using a hemocytometer, manual coagulation testing, electrophoresis, and thin layer chromatography all require additional controls.



Microbiology QC Under CLIA



- For **microbiological media**, CLIA regulations for media [42 CFR 493.1256 (e)(4)(i-iii)] state the laboratory must:
 - **Check each batch of media for sterility** if sterility is required for testing;
 - **Check each batch of media for its ability to support growth** and, as appropriate, **select or inhibit specific organisms or produce a biochemical response**; and
 - Document the physical characteristics of the media when compromised and report any deterioration in the media to the manufacturer.
- For **microbiology AST** the CLIA requirements at §493.1261(b)(1-2) state laboratory must check;
 - Each batch of media and each lot/shipment of antimicrobial agent(s) before, or concurrent with, initial use, using approved control organisms;
 - **Each day tests are performed**, use appropriate control organism(s) to check the procedure; zone sizes or MICs must be within established limits before reporting patient results.



asm.org/agarart

Problems with CLIA QC: Microbiological media

- A large study (documented in CLSI M22-A3 and independent publications) shows that most media QC failures are due to QC strain failure.
- The actual failure rate for commonly-used media is well under .5%.
 - Jones RN, Krisher K, Bird DS; College of American Pathologists Microbiology Resource Committee. Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001). Arch Pathol Lab Med. 2003 Jun;127(6):661-5.
- An 'exempt media' class was described in CLSI M322-A3

Table 3. Raw and Extrapolated Lot Failure Rates for 38 Media With Significant Quality Control (QC) Experience Data as Defined by ≥ 1000 Lots or $\geq 100\,000$ Items Screened

| Medium | No. of Items | No. of Lots | No. of Lots Failed With Reason | | Failure Rates, % | |
|---|--------------|-------------|--------------------------------|------------|------------------|---------------|
| | | | Total | QC Strains | Raw | Extrapolated* |
| Chocolate | 15 710 003 | 62 119 | 137 | 64 | 0.36 | 0.17† |
| Thayer-Martin | 1 771 833 | 26 761 | 98 | 76 | 0.64 | 0.49† |
| BACTEC bottle | 1 458 169 | 4658 | 6 | 2 | 0.79 | 0.26† |
| CVA | 1 243 778 | 18 002 | 57 | 47 | 0.73 | 0.60 |
| LIM broth (Todd-Hewitt with CNA) | 1 083 196 | 4793 | 18 | 14 | 0.31 | 0.24† |
| MacConkey with sorbitol | 1 038 153 | 19 346 | 34 | 20 | 1.04 | 0.61 |
| Campy blood (Blaser) | 1 028 332 | 20 406 | 76 | 57 | 0.72 | 0.54 |
| Selective strep agar | 878 304 | 6781 | 13 | 5 | 0.10 | 0.04† |
| Martin-Lewis | 851 763 | 8053 | 15 | 15 | 0.52 | 0.52 |
| BacT/Alert bottle | 742 626 | 995 | 6 | 3 | 0.10 | 0.05† |
| CDC laked blood with kanamycin and vancomycin | 453 158 | 7145 | 16 | 9 | 0.36 | 0.20† |
| GC-II (CA/IsoVitaleX) | 439 831 | 1679 | 14 | 7 | 1.37 | 0.68 |
| CDC sheep blood with kanamycin and vancomycin | 436 336 | 7132 | 26 | 11 | 0.42 | 0.18† |
| <i>Bacteroides bile esculin</i> | 419 733 | 7472 | 18 | 8 | 0.39 | 0.14† |
| <i>Brucella</i> with hemin and vitamin K | 399 979 | 3639 | 11 | 3 | 0.41 | 0.11† |
| CDC sheep blood with PEA | 383 557 | 6504 | 13 | 5 | 2.03 | 0.78 |
| Inhibitory mold agar | 381 494 | 3934 | 8 | 5 | 0.64 | 0.40† |
| Kanamycin laked blood | 365 545 | 3110 | 10 | 4 | 0.39 | 0.15† |
| <i>Brucella</i> agar | 352 424 | 2760 | 8 | 4 | 0.25 | 0.13† |
| Todd-Hewitt | 300 131 | 2130 | 6 | 4 | 0.94 | 0.63 |
| GC-Lect agar | 281 869 | 2815 | 17 | 11 | 0.46 | 0.30† |
| SXT agar | 279 062 | 2551 | 15 | 5 | 0.31 | 0.10† |
| BHI with sheep blood with chloramphenicol and gentamicin | 258 575 | 3494 | 19 | 6 | 0.34 | 0.17† |
| TSA with sheep blood with ampicillin | 247 849 | 1102 | 13 | 2 | 2.00 | 0.31† |
| TCBS (<i>Vibrio cholerae</i>) | 205 251 | 3073 | 19 | 9 | 0.65 | 0.27† |
| SAB with chloramphenicol and gentamicin | 166 592 | 2018 | 6 | 2 | 0.25 | 0.08† |
| <i>Brucella</i> laked blood with kanamycin and vancomycin | 163 797 | 2444 | 18 | 7 | 0.83 | 0.33† |
| Charcoal selective | 133 839 | 2372 | 12 | 7 | 0.67 | 0.39† |
| Nutrient broth | 125 398 | 985 | 2 | 2 | 1.32 | 1.32 |
| Reagan-Lowe agar | 52 044 | 3853 | 13 | 8 | 2.10 | 1.29 |
| <i>Legionella</i> selective | 76 485 | 2371 | 13 | 9 | 0.55 | 0.38† |
| Potato dextrose agar | 92 335 | 1877 | 6 | 2 | 1.49 | 0.50† |
| PC (<i>Burkholderia cepacia</i>) | 44 245 | 1867 | 4 | 4 | 0.48 | 0.48† |
| Cornmeal with Tween | 57 659 | 1737 | 9 | 5 | 2.42 | 1.34 |
| Cornmeal | 34 842 | 1722 | 7 | 2 | 1.16 | 0.33† |
| Egg yolk (modified) | 50 580 | 1346 | 7 | 3 | 0.59 | 0.25† |
| Inhibitory mold agar with gentamicin | 95 156 | 1232 | 2 | 1 | 0.24 | 0.12† |
| BHI with sheep blood with CC | 82 059 | 1087 | 8 | 4 | 1.47 | 0.74 |

* Extrapolated failure rate represents that rate resulting from QC organism testing and excludes other reasons, such as sterility, hemolysis, surface effects, etc.

† Failure rates meeting the criteria for exemption as published previously by the NCCLS M22-A¹ derived from earlier CAP statistics² and expanded to $\leq 0.50\%$ by the NCCLS in 2003.

Problems with CLIA QC: Cartridge-based test systems

A system with a dozen testing modules (what exactly is a test system anyway?*)

Each cartridge costs ~\$150

Each cartridge tests 20+ targets. Does each target need QC?

Even if just 2 controls/d (not necessarily realistic; you can't really put 22 targets in one molecular control) that's \$110,000/year in control testing.

All the reagents are in the cartridge, with internal controls, so if you QC one cartridge, you've QCed -- one cartridge.

* I am **so** not getting into that here.



THE BIOFIRE RESPIRATORY 2.1 PANEL MENU

Overall 97.1% sensitivity and 99.3% specificity (prospective specimens) ¹

SARS-CoV-2 98.4% PPA and 98.9% NPA²

Sample Type: Nasopharyngeal swab in transport media or saline

VIRUSES:

- Adenovirus
- Coronavirus 229E
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus OC43
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A virus
- Influenza A virus A/H1
- Influenza A virus A/H3
- Influenza A virus A/H1-2009
- Influenza B virus
- Parainfluenza virus 1
- Parainfluenza virus 2
- Parainfluenza virus 3
- Parainfluenza virus 4
- Respiratory syncytial virus

BACTERIA:

- Bordetella parapertussis
- Bordetella pertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae



Enter the IQCP...

- There's an older solution to this problem called EQC, Equivalent Quality Control. No longer allowed, mentioned for historical purposes.
- CMS/CLIA offers IQCP
- **IQCP stands for Individualized Quality Control Plan.**
- Performing an IQCP 'customizes a QC Plan for a nonwaived test in its unique environment, and offers laboratories flexibility in achieving QC compliance.'

IDK...

So exactly what does an IQCP apply to?



What Test Systems are Eligible for an IQCP

- Test must:
 - Be nonwaived. Waived tests are not eligible for (and do not need) an IQCP. Use manufacturer's recommendations and you're good.
 - Be in a subspecialty other than pathology or cytology.
 - Follow manufacturer's instructions at least.
 - Testing must employ an internal quality control system; electronic, procedural, or built-in, except for microbiology media and reagents.
 - If your QC policy is equal to or more stringent than the CLIA control requirements, an IQCP not required.
 - You can still do one if you want. 😞
- If it doesn't meet these criteria, it's not eligible and you must do regular QC; at least daily or each run.

When Do You Need an IQCP?

- Whenever the manufacturer recommends QC less frequently than the CLIA requirements AND
- You want to reduce your QC requirements below the CLIA required ones.
- If the answer to either is 'no', **you don't need an IQCP.**



Question 2

- You get an email in your microbiology list serve. It reads:

From: <an excellent microbiologist>

Sent: Monday, August 22, 2022 1:06 PM

To: <a whole bunch of microbiologists>

Subject: <company name> IQCP Request

Hello,

Anyone having a <very good MALDI-TOF bacterial identification system>, would you be willing to share your IQCP? With an extreme staffing shortage and the ongoing COVID testing we are all facing, I have fallen so far behind and our inspection is fast approaching. I would be eternally grateful! Thank you in advance 😊.

- How would you answer this? Answer in the poll (as few words as possible) and it'll generate a Wordcloud!

WT

CENSORED

The Elements of an IQCP

- The IQCP consists of three parts:
 - Risk Assessment (RA)
 - Quality Control Plan (QCP), and
 - The IQCP QCP cannot be less stringent than the manufacturer's instructions.
 - Quality Assessment (QA)



What's a Risk Assessment?

A tool for describing risks associated with laboratory testing processes and identifying mitigation strategies.





How To Do A Risk Assessment

- A risk assessment for IQCP is not confined to the QC process.
- Must include risk evaluation:
 - Preanalytical, analytical, postanalytical risks
- And risk mitigation assessment
 - Mitigation strategies for unacceptable risks
- Data Sources
 - Manufacturers / Regulatory data
 - Laboratory experience / QC / PT data for existing systems
 - Laboratory quality monitors; temperature, etc.
 - Publications
 - Clinical information, applications, potential for impact
- Examples to come (by no means exhaustive!)
- The techniques of risk analysis can be applied well beyond IQCP, even beyond the lab.

Risk Matrix

Frequency of error occurrence:

Unlikely (once every 2-3 years)

Occasional (once per year)

Probable (once per month)

Frequent (once a week)

Severity of harm to patient:

Negligible (temporary discomfort)

Minor (temporary injury; not requiring medical intervention)

Serious (impairment requiring medical intervention)

Critical (life threatening consequences)

| Freq./Severity of Harm | Negligible | Minor | Serious | Critical |
|------------------------|----------------|----------------|----------------|----------------|
| Frequent | Not Acceptable | Not Acceptable | Not Acceptable | Not Acceptable |
| Probable | Acceptable | Not Acceptable | Not Acceptable | Not Acceptable |
| Occasional | Acceptable | Acceptable | Acceptable | Not Acceptable |
| Unlikely | Acceptable | Acceptable | Acceptable | Acceptable |

Examples of Preanalytical risks

| Risk Factor (Possible Sources of Error) | | Frequency of error occurrence | Severity of harm to patient | Risk Level |
|---|---|--|--------------------------------|----------------|
| Preanalytical | | | | |
| Specimen (Primary): | | | | |
| Patient identification | | probable | serious | Not Acceptable |
| Collection/container/volume | | frequent | negligible | Not Acceptable |
| Integrity | | frequent | negligible | Not Acceptable |
| Transport | | frequent | negligible | Not Acceptable |
| Storage | | probable | negligible | Acceptable |
| Specimen (Organism): | | | | |
| Sample Stability | | frequent | minor | Acceptable |
| Inappropriate Transport Conditions/Media | | unlikely | minor | Acceptable |
| Improper or insufficient sample collection. | | frequent | minor | Not Acceptable |
| Sample Stability | | frequent | minor | Not Acceptable |
| Possible Sources of Error | | How can identified sources of error be reduced? | | |
| Risk Factor | Possible Error | | | |
| Preanalytical | | | | |
| 1A: Specimen - Biological | <ul style="list-style-type: none"> Improper specimen procurement/handling/processing | <ul style="list-style-type: none"> Adhere to procedures in SOP #2.1.1 that addresses patient identification and specimen collection, labeling, transport, storage and remedial actions to control improperly handled specimens or delayed specimens. Annually review representative specimen processing errors (N=10 to 15) with all staff involved with patient specimens. During initial training and competency assessment, emphasize: Proper specimen handling/processing is the most critical part of any test Failure to set up and inoculate test properly may result in delayed or inaccurate results | | |

From ASM/CAP/CLSI Template: IQCP for QC for molecular test system XYZ

Examples of Analytical Risks

| Risk Factor (Possible Sources of Error) | Frequency of error occurrence | Severity of harm to patient | Risk Level |
|--|----------------------------------|--------------------------------|--------------|
| Analytical | | | |
| Testing Personnel: | | | |
| Training | unlikely | serious | Acceptable |
| Competency | unlikely | serious | Acceptable |
| Reagents: | | | |
| Shipping/receiving | occasional | minor | Acceptable |
| Storage | unlikely | serious | Acceptable |
| QC strain storage/prep | occasional | negligible | Acceptable |
| PCR Template/Amplicon Contamination | Occasional | Minor | Acceptable |
| Environment: | | | |
| Temperature/airflow/humidity/ ventilation | occasional | negligible | Acceptable |
| Utilities | occasional | minor | Acceptable |
| Test System: | | | |
| Extraction failure | Occasional | Minor | Acceptable |
| Contamination during sample prep | Probable | Minor | Unacceptable |
| Change in pathogen target sequences | unlikely | serious | Acceptable |

Examples of Analytical Risk Mitigation

| Possible Sources of Error | | How can identified sources of error be reduced? |
|---------------------------|--|---|
| Risk Factor | Possible Error | |
| Analytical | | |
| 3: Reagents | | During initial training and competency assessment, emphasize standard rules to always: <ul style="list-style-type: none"> • Take responsibility for reagents/supplies (all staff) • Maintain reagents at proper storage conditions • Check expiration dates • Perform required QC |
| Receiving/storage | <ul style="list-style-type: none"> • Incorrect ordering • Depleted reagent supply • Reagent integrity compromised | Designated staff member(s) assigned to inventory (order/receipt) materials to ensure supply is properly maintained and testing materials are handled appropriately on receipt |
| Expiration dates | | See above (Reagents) |
| Preparation/use | Use of incorrect cartridge for analyte | Use color codes / labels on boxes of cartridges |

Examples of Postanalytical Risks

| Risk Factor (Possible Sources of Error) | Frequency of error occurrence | Severity of harm to patient | Risk Level |
|---|----------------------------------|--------------------------------|----------------|
| Postanalytical | | | |
| Test Results: | | | |
| Test reporting delays | occasional | minor | Acceptable |
| Transmission of results to Electronic Health Record | occasional | serious | Acceptable |
| Review reported results | frequent | serious | Not Acceptable |
| No results (Due to amplification/method failure) | Probable | Serious | Unacceptable |
| Environmental Contamination (Quality Failure) | Occasional | Serious | Acceptable |
| Clinician feedback | unlikely | serious | Acceptable |

Examples of Postanalytical Risk Mitigation

| Possible Sources of Error | | How can identified sources of error be reduced? |
|---|---|---|
| Risk Factor | Possible Error | |
| Postanalytical | | |
| 6: Test Results | | <ul style="list-style-type: none"> • Supervisor maintains summary of incorrect results released and meets with laboratory director monthly to review this summary • During initial training and competency assessment, emphasize timely reporting of both preliminary results and final reports |
| Test reporting delays | Results delayed beyond that expected for organism type | See above (Test Results) |
| Transmission of results to Electronic Health Record | <ul style="list-style-type: none"> • Incorrect transmission of results • Delay in transmission of results | See above (Test Results) |
| Review reported results | <ul style="list-style-type: none"> • Erroneous results reported | See above (Test Results) |
| Clinician feedback | Complaints/suggestions regarding delayed or potential erroneous results | See above (Test Results) <ul style="list-style-type: none"> • Incorporate suggestions into QA plan, as appropriate. |

Question 3

- The Coagulation clinic requests to be able to monitor prothrombin time. You find them the CLIA-waived Magic Clotter system, and start discussing implementation with your medical director. What post-analytic risks would you incorporate into your IQCP risk assessment?



Question 3

- T
t
t
w
s
w

Trick Question!

It's waived, so no IQCP!

post-analytic risks would you incorporate into your IQCP risk assessment?

Question 3.1

- The Coagulation clinic requests to be able to monitor prothrombin time. You find them the **moderate complexity** Magic Clotter system, and start discussing implementation with your medical director. What post-analytic risks would you incorporate into your IQCP risk assessment?
- Answer in the poll (as few words as possible) and it'll generate a Wordcloud!



What's a Quality Control Plan?

- A written document describing practices and procedures:
 - To reduce failures and errors in testing processes
 - To detect errors and defects in testing processes when they occur
 - To ensure accurate, reliable results
- Includes:
 - QC appropriate to the test system
 - PT
 - Maintenance
 - Training
 - Corrective actions



Example Quality Control Plan

Final QCP for Cartridge based molecular test system XYZ

Based on our risk assessment and Quality Assessment, the QCP consists of following the instructions that are provided in explicit detail in SOP #5.1.7 “XYZ System for Molecular Detection of Microbe Q”. Positive and negative QC testing will be performed at least monthly on each instrument.

Testing of appropriate QC materials on each new lot/shipment of cartridges before or concurrently with placing these materials into use for testing patient specimens.

Testing of appropriate QC materials on each cartridge type after major system maintenance or software upgrade before or concurrently with placing the equipment back into service.

Recording and evaluating QC results according to QC acceptability criteria as defined in #5.1.7 “XYZ System for Molecular Detection of Microbe Q”. Any abnormal result is immediately investigated.

System XYZ is subscribed to PT challenge WNO. Any unacceptable result is immediately investigated according to lab policy #13-1313

System XYZ has a service contract with the vendor. PM and service is monitored in the service maintenance log.

Training and competence for system XYZ are incorporated into the service training and competency forms. Training and competency will be monitored and any deficiencies rectified immediately.

Question 4

- You're gathering data for an IQCP on a novel iPTH system for the OR. The manufacturer's instructions say you can recalibrate and run QC on a monthly basis. As you do daily QC to verify stability, the system starts to drift by more than 20% on the high control after 3 weeks. You repeat the stability study and the same thing happens. How would you handle this?
- Answer in the poll (as few words as possible) and it'll generate a Wordcloud!



What's Quality Assessment?

- The process of continuously monitoring effectiveness of the IQCP.
- Includes:
 - Review of QC
 - Review of PT
 - Review of any other relevant data; complaints, errors, etc.
- Reviewed and signed-off annually by laboratory director.



Example QA Plan

Quality Assessment: Ongoing Monitoring for QCP Effectiveness (Performed by supervisor and/or section head)

Reasons for QC failures, PT failures, and patient result reporting errors will be examined and addressed as needed in a new/updated risk assessment: 1) Has a new risk factor been identified? 2) Does this change the frequency of risk? 3) Does the risk factor change the potential severity of harm to patient?

Daily review of patient results for reporting errors and clinician complaints. Take corrective action and revise QCP as needed.

Monthly review of QC results by supervisor or section head. Take corrective action and revise QCP when unexpected QC failures indicate adjustment to the QC plan defined herein is needed.

Regular review of Proficiency Testing results. Take corrective action and revise QCP if necessary, when PT results are not acceptable.

Monthly review of all equipment maintenance/monitoring logs according to standard laboratory protocols. Take corrective action and revise QCP as needed.

Daily monitoring and recording of instrument (room) and cartridge storage temperatures. Any out-of-range result is investigated and reported to the supervisor.

Regular training and competency assessment according to standard laboratory protocols. Modify training and revise QCP as needed.

Continual participation in this institution's quality program that addresses specimen handling and erroneous specimen labeling. Take corrective action and revise QCP as needed.

This QCP has been reviewed and is approved by the laboratory director (as named on the CLIA license).

Signature

Date



FTW!

IQCP Resources

- ASM/CAP/CLSI Q&A and templates at:
 - <https://asm.org/Protocols/Individualized-Quality-Control-Plan-IQCP>
- CAP IQCP FAQs
 - <https://documents.cap.org/documents/iqcp-faqs.pdf>
- CMS IQCP Resources
 - [https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Individualized Quality Control Plan IQCP](https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Individualized%20Quality%20Control%20Plan%20IQCP)
- **CAP staff tell me that IQCP is still one of the most-questioned areas. Don't be afraid to ask, you're in good company.**



Sources

- <https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/FAQs-IQCP.pdf>
- <https://documents.cap.org/documents/iqcp-faqs.pdf>
- <https://asm.org/Protocols/Individualized-Quality-Control-Plan-IQCP>